Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Myovant sciences ltd. symbols : Pfe save search
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Published: 2022-08-06 (Crawled : 04:20) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
| Email alert
Add to watchlist
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
myfembree treatment fda sciences management approval
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Published: 2022-06-17 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 3.13%
H: 8.66%
C: 6.63%
sciences women lancet therapy publication phase 3
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Published: 2022-06-02 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -2.98%
H: 0.0%
C: 0.0%
myfembree fda sciences drug application
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Published: 2022-05-06 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -2.36%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: 0.0%
myfembree management drug application
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Published: 2022-04-12 (Crawled : 05:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.17%
H: 1.18%
C: -0.36%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -22.06%
H: 9.34%
C: -3.89%
myfembree management drug application
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Published: 2021-10-19 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.68%
H: 1.44%
C: 1.18%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.3%
H: 3.0%
C: -0.15%
uterine fibroids therapy
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Published: 2021-09-09 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.09%
H: 0.53%
C: -0.95%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.54%
H: 1.56%
C: -2.22%
new drug fda fda acceptance drug
Alpha Healthcare and Humacyte Announce Nominees for Election to Post-Merger Public Company Board of Directors
Published: 2021-08-13 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.11%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
F | News | $12.95 0.08% 2.55% 74M
|
Consumer Durables
|
| O: 0.04%
H: 0.0%
C: 0.0%
CS | $0.8858 1.49% 64M
|
Finance
|
| O: -0.34%
H: 0.0%
C: 0.0%
EXAS | $63.24 -0.46% -0.46% 1.2M
|
Health Technology
|
| O: 1.64%
H: 0.0%
C: 0.0%
DMTK 4 | $0.616 3.81% 72K
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
NMTR | $0.0722 -42.97% -67.9% 10M
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
merge
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
Published: 2021-05-26 (Crawled : 21:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.1%
H: 0.03%
C: -0.94%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.26%
H: 8.97%
C: 3.63%
treatment fda bleeding fda approval approval menstrual bleeding
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Published: 2021-04-12 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.33%
H: 1.52%
C: 1.34%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.39%
H: 0.5%
C: -4.98%
phase 3 contraceptive
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published: 2021-03-24 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.34%
H: 1.27%
C: 0.37%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.3%
H: 1.17%
C: -7.12%
positive therapy women phase 3
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published: 2021-02-17 (Crawled : 22:04) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.32%
H: 0.28%
C: -0.63%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.89%
H: 3.7%
C: 3.11%
therapy women phase 3
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2021-01-26 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.03%
H: 0.89%
C: 0.11%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 4.44%
H: 9.52%
C: 4.67%
positive therapy phase 3
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Published: 2020-12-28 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.24%
H: 0.59%
C: -1.45%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 32.66%
H: 2.39%
C: -9.18%
collaboration commercialization announces collaboration health
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.